LD Organisation

Scientific Conference Producers

Scientific Programme


Target Selection: Hit to Lead: Identification, development

08:00

Registration

09:30

Opening

Session Chair

Prof. André TARTAR
UNIVERSITY LILLE 2, Lille, France
10:00

Vascular Tumor Targeting

Prof. Dario NERI
ETH ZÜRICH, Zürich, Switzerland
10:45

Coffee Break

Session Chair

Dr Marcel HIBERT
FACULTE DE PHARMACIE, Illkirch, France
11:15

Novel Antagonists of Protease Activated Receptors 1: Unusual GPCRs Implicated in Cardiovascular Diseases

Dr Michel PEREZ
PIERRE FABRE, Toulouse, France
12:00

Identification of Functionally Selective Alpha2C-AR Agonists as Potential New Drugs for Treatment of Pain

Dr Eric JNOFF
UCB PHARMA SA, Braine-l'Alleud, Belgium
12:45

Lunch and Poster Session

Session Chair

Dr. Robert H. DODD
ICSN CNRS, Gif-Sur-Yvette, France
14:15

Pyrrolopyrimidine-Based P2X3 Antagonists for the Treatment of Pain

Dr Louis-David CANTIN
ASTRAZENECA R&D, Montréal, Canada
15:00

Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target

Dr Maxwell CUMMINGS
TIBOTEC, Mechelen, Belgium
15:45

Coffee Break and Poster Session

Session Chair

Dr Luc VAN HIJFTE
JANSSEN RESEARCH & DEVELOPMENT, Nijmegen, The Netherlands
16:30

Indole-carboxylic Acid Amides as Novel CETP Inhibitors: From Hit to Clinical Candidate and Beyond

Dr Philippe PFLIEGER
F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland
17:15

Inhibitors of PKC-beta and GSK-3beta: A Tale of Two Kinases

Dr Bruce MARYANOFF
SCRIPPS, San Diego, United States
18:30

Cocktail and Poster Session (Faculty of Pharmacy)

09:45

Start of parallel sessions

Section A
Synthetic Chemistry: new frontiers impacting drug discovery
Section B
Screening, managing structure-properties relationship
Section A
Synthetic Chemistry: new frontiers impacting drug discovery
Session Chair
Dr Bruno FIGADERE
UNIVERSITÉ PARIS-SUD, Chatenay-Malabry, France
Section B
Screening, managing structure-properties relationship
Session Chair
Prof. Olivier DUVAL
, Angers, France

Session Chair

Prof. Dario NERI
ETH ZÜRICH, Zürich, Switzerland
16:00

Sugars and Proteins

Prof. Benjamin DAVIS
OXFORD UNIVERSITY, Oxford, United Kingdom
16:45

End of Conference

17:15

Departure by bus to visit the “Taittinger wine cellars” (for pre-registrated participants)

17:30

Visit of "Caves Taittinger"

20:00

Banquet

20:00

Banquet in the “Demeure des Comtes de Champagne” (18-22 rue de Tambour, 511100 Reims, near the City Hall)

In parallel:
14:00-15:30 - JOB Forum

Dr Patrick PLE
ASTRA ZENECA, Reims, France
Dr Laurent JEANNIN
SOLVAY, Belgium
Mr Térence BEGHYN
UNIVERSITY LILLE 2, Lille, France

Case-Studies from Bench to Bedside

Session Chair

Dr Edmond DIFFERDING
FORMELY WITH UCB, Louvain-la-Neuve, Belgium
09:00

The First NO- and Heam-independent Activator of Soluble Guanylate Cyclase for the IV Treatment of Acute Heart Failure

Dr Michael G. HAHN
BAYER HEALTHCARE, Wuppertal, Germany
09:45

A Single Synthetic Peptide for Immunomodulating Lupus, a Complex Autoimmune Disease

Dr Sylviane MULLER
IBMC-CNRS, Strasbourg, France
10:30

Coffee Break

Session Chair

Dr Dominique LESUISSE
SANOFI AVENTIS, Chilly-Mazarin, France
11:00

The Identification of Selective p38 MAPK Inhibitors with High Blood Potency Suitable for Clinical Development: The Discovery of Losmapimod

Dr Vipul K. PATEL
GLAXOSMITHKLINE, Stevenage, United Kingdom
11:45

Telbivudine, a Potent and Specific Anti-HBV Nucleoside Analogue: From the Bench to its Marketing Approvals (Tyzeka®, Sebivo®)

Dr Gilles GOSSELIN
IDENIX SARL, Montpellier, France
12:30

Discovery of Inhibitors of MAPKAPK5, a Novel Target for Rheumatoid Arthritis

Dr Martin ANDREWS
GALAPAGOS NV, Mechelen, Belgium
13:15

Conclusions
End of the Symposium